Monograph
C01CA14 - Dopexamine |
Propably not porphyrinogenic |
PNP |
Rationale
Catecholamine. Non-CYP metabolism. No data pointing to CYP-interaction.
Chemical description
Catecholamine.
Therapeutic characteristics
Synthetic catecholamine used in intravenous short-duration treatment of chronic heart failure. Administered in infusion 1-6 ug/kg/minute in 0.9 %NaCl or 5% glucose solution.
Metabolism and pharmacokinetics
Metabolized in the liver via O-methylation and O-sulfatation of the catechol hydroxyl group. Half time in blood 6-7 minutes.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
United Kingdom© NAPOS 2024